EURIPRED
European Research Infrastructures for Poverty Related Diseases
| Coordinatore | Department of Health
Organization address
address: "Quarry House, Quarry Hill" contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 10˙962˙402 € |
| EC contributo | 8˙484˙910 € |
| Programma | FP7-INFRASTRUCTURES
Specific Programme "Capacities": Research infrastructures |
| Code Call | FP7-INFRASTRUCTURES-2012-1 |
| Funding Scheme | CP-CSA-Infra |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-11-01 - 2017-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Department of Health
Organization address
address: "Quarry House, Quarry Hill" contact info |
UK (Leeds) | coordinator | 2˙097˙803.00 |
| 2 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 744˙704.00 |
| 3 |
ICOSAGEN AS
Organization address
address: NOORUSE 9 contact info |
EE (TARTU) | participant | 454˙223.20 |
| 4 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 453˙739.00 |
| 5 |
KENYA MEDICAL RESEARCH INSTITUTE
Organization address
address: Off Mbagathi Way contact info |
KE (Nairobi) | participant | 420˙541.38 |
| 6 |
FEDERAL STATE BUDGETARY EDUCATIONAL INSTITUTION OF HIGHER PROFESSIONAL EDUCTAION STATE UNIVERSITY OF MANAGEMENT
Organization address
address: RYAZANSKY PROSPECT 99 contact info |
RU (MOSKVA) | participant | 410˙559.40 |
| 7 |
LIONEX GMBH
Organization address
address: Salzdahlumer Strasse 196 contact info |
DE (BRAUNSCHWEIG) | participant | 389˙060.00 |
| 8 |
JPT PEPTIDE TECHNOLOGIES GMBH
Organization address
address: VOLMERSTRASSE 5 UTZ contact info |
DE (BERLIN) | participant | 386˙758.10 |
| 9 |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
UK (LONDON) | participant | 372˙443.44 |
| 10 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 371˙419.20 |
| 11 |
INSTITUTO DE SALUD CARLOS III
Organization address
address: CALLE SINESIO DELGADO 4-6 contact info |
ES (MADRID) | participant | 368˙889.12 |
| 12 |
STICHTING TUBERCULOSIS VACCINE INITIATIVE
Organization address
address: Runderweg 6 contact info |
NL (LELYSTAD) | participant | 367˙067.97 |
| 13 |
EATRIS ERIC
Organization address
address: DE BOELELAAN 1118 contact info |
NL (AMSTERDAM) | participant | 365˙323.03 |
| 14 |
UNIVERSITE DE LAUSANNE
Organization address
city: LAUSANNE contact info |
CH (LAUSANNE) | participant | 357˙647.03 |
| 15 |
"NATIONAL CENTER FOR AIDS/STD CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION"
Organization address
address: CHANGBAI ROAD 155 contact info |
CN (BEIJING) | participant | 339˙085.20 |
| 16 |
THE D.I. IVANOVSKY INSTITUTE OF VIROLOGY OF THE MINISTRY OF THE HEALTHOF THE RUSSIAN FEDERATION
Organization address
address: GAMALEYA UL 16 contact info |
RU (MOSKVA) | participant | 312˙767.00 |
| 17 |
POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH
Organization address
address: DONAUSTRASSE 99 contact info |
AT (KLOSTERNEUBURG) | participant | 272˙025.00 |
| 18 |
STICHTING EATRIS
Organization address
address: LAAN VAN NIEUW OOST INDIE 334 contact info |
NL (DEN HAAG) | participant | 856.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'HIV/AIDS, Tuberculosis (TB) and Malaria alone account for more than six million deaths worldwide every year. Despite substantial efforts made in recent years, Poverty Related Diseases are still spreading. New therapeutic interventions are therefore urgently required to combat Poverty Related Diseases. The existence of a well-developed HIV/TB/Malaria infrastructure presents a prime opportunity to address other sexually transmitted diseases such as viral hepatitis efficiently and effectively. The overall goal of the EURIPRED is to coordinate and integrate international resources into a single specialised infrastructure to support European HIV, TB, Malaria and Hepatitis B virus and Hepatitis C virus studies from early drug, vaccine and microbicide discovery to clinical trials. This will be achieved by creating partnerships between European scientists and international research teams from disease endemic countries and strong collaborations between industry and public sector research. Although vaccines, drugs and microbicide research is being conducted in the European Union (EU) there is no single European infrastructure that brings international resources and facilities together to develop cost-effective products for the European market. To underpin this need, EURIPRED will integrate worldwide resources to allow European access to shared reagents. This integrated approach will strengthen international cooperation, increase research capacity in EU and developing countries and significantly contribute to the European Research Area (ERA). By minimising fragmentation and duplication of research efforts and pooling fragmented resources EURIPRED can improve European research efficiency and effectiveness. EURIPRED will be built upon the highly successful model of the Centre for AIDS Reagents (CFAR), a twenty-three year old reagent initiative based at the National Institute of Biological Standards and Control (NIBSC), a centre of the Medical Healthcare Products Regulatory Authority Agency (MHRA) and will comprise of a world-class team of experts and repositories with expertise in vaccine, microbicide and drug development for a range of infectious diseases. By engaging international scientific communities, EURIPRED can play a leading role in driving research forward in Europe and beyond.'